Stockchase InsightsMedpace HoldingsMEDPBUYJan 08, 2024

MEDP is a clinical research company that helps smaller biotechs perform research and navigate/move along the pathway to commercialization. They tend to focus on smaller companies, so they tend to feel the booms and busts a bit more than peers but we view it as a solid company that has navigated the last few years well. Fundamentals are quite strong as well and the growth on the top-line is solid in the 15% range over the next two years expected. We think the big question comes down to valuation at 30X forward earnings. We would be comfortable buying it based on the outlook for its earnings and interest rates. 
Unlock Premium - Try 5i Free